‘All illness is personal to that individual’: a qualitative study of patients’ perspectives on treatment adherence in bronchiectasis

McCullough, Amanda; Tunney, Michael; Elborn, J. Stuart; Bradley, J.M.; Hughes, Carmel

doi:10.1111/hex.12217

Cited by 23 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently published qualitative study we conducted found that beliefs about the necessity for treatment and concerns about the side-effects of treatment influenced patients' decisions about adherence in bronchiectasis [20]. We also reported that other factors such as patients' perceptions of disease, symptoms and quality of life affected adherence decisions [20]. Furthermore, the practicalities of treatment including treatment burden, particularly for younger people completing treatments around work or caring commitments, were barriers to adherence [20].…”

Section: Introductionmentioning

confidence: 84%

“…In asthma, chronic obstructive pulmonary disease (COPD) and CF, patients' beliefs about necessity for treatment and concerns about side-effects and/or long term effects of treatment are predictors of adherence to both inhaled treatments [16,17] and airway clearance [18,19]. A recently published qualitative study we conducted found that beliefs about the necessity for treatment and concerns about the side-effects of treatment influenced patients' decisions about adherence in bronchiectasis [20]. We also reported that other factors such as patients' perceptions of disease, symptoms and quality of life affected adherence decisions [20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of adherence to treatment in bronchiectasis

McCullough

Tunney

Elborn

et al. 2015

Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

Beliefs about treatment, age, number of prescribed medications and perceived treatment burden predicted subsequent adherence in bronchiectasis, thereby, providing potential targets for future interventions in this population. Clinicians can use these data to identify patients with bronchiectasis who might be at risk of non-adherence i.e. those who are younger, have concerns about medications, who do not think airway clearance is necessary or who are prescribed numerous medications.

show abstract

Section: Introductionmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Predictors of adherence to treatment in bronchiectasis

McCullough

Tunney

Elborn

et al. 2015

Respiratory Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The treatment burden associated with nebulised therapies, which include both the time to administer the dose and also to care for the machinery, are substantial and impact on compliance. MCCULLOUGH et al [88] assessed compliance in 75 patients with bronchiectasis and found self-reported adherence of 52% for inhaled antibiotics and 39% for airway clearance . Patients treated with inhaled antibiotics should be assessed for adherence, medication-related adverse effects (e.g.…”

Section: Inhaled Antibioticsmentioning

confidence: 99%

Management of bronchiectasis in adults

2015

View full text Add to dashboard Cite

Formerly regarded as a rare disease, bronchiectasis is now increasingly recognised and a renewed interest in the condition is stimulating drug development and clinical research. Bronchiectasis represents the final common pathway of a number of infectious, genetic, autoimmune, developmental and allergic disorders and is highly heterogeneous in its aetiology, impact and prognosis.The goals of therapy should be: to improve airway mucus clearance through physiotherapy with or without adjunctive therapies; to suppress, eradicate and prevent airway bacterial colonisation; to reduce airway inflammation; and to improve physical functioning and quality of life.Fortunately, an increasing body of evidence supports interventions in bronchiectasis. The field has benefited greatly from the introduction of evidence-based guidelines in some European countries and randomised controlled trials have now demonstrated the benefit of long-term macrolide therapy, with accumulating evidence for inhaled therapies, physiotherapy and pulmonary rehabilitation.This review provides a critical update on the management of bronchiectasis focussing on emerging evidence and recent randomised controlled trials. @ERSpublications Bronchiectasis is a rapidly developing field: review of recent RCTs and progress towards developing new therapies

show abstract

“…>96% of respondents felt that their bronchiectasis could be better managed through having a self-management plan co-designed with their HCP, and access to physiotherapy/pulmonary rehabilitation, which also includes teaching them how to use techniques/equipment at home [1,22,40,68,69]. Self-management plans facilitated by good communication between patients and HCPs empower patients to manage and cope with their condition more confidently and independently [70,71]. An important component of these self-management strategies and of reducing hospitalisation is the awareness of HCPs of bronchiectasis and available and appropriate community care and physiotherapy services [1,68,72].…”

Section: Condition Managementmentioning

confidence: 99%

Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration

et al. 2016

View full text Add to dashboard Cite

Bronchiectasis is a disease of renewed interest in light of an increase in prevalence and increasing burden on international healthcare systems. There are no licensed therapies, and large gaps in knowledge in terms of epidemiology, pathophysiology and therapy. The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) is a European Respiratory Society (ERS) Clinical Research Collaboration, funded by ERS to promote high-quality research in bronchiectasis. The objective of this consensus statement was to define research priorities in bronchiectasis. From 2014 to 2015, EMBARC used a modified Delphi process among European bronchiectasis experts to reach a consensus on 55 key research priorities in this field. During the same period, the European Lung Foundation collected 711 questionnaires from adult patients with bronchiectasis and their carers from 22 European countries reporting important research priorities from their perspective. This consensus statement reports recommendations for bronchiectasis research after integrating both physicians and patients priorities, as well as those uniquely identified by the two groups. Priorities identified in this consensus statement provide the clearest possible roadmap towards improving our understanding of the disease and the quality of care for patients with bronchiectasis. @ERSpublications EMBARC consensus statement identifies research priorities in bronchiectasis as determined by physicians and patients

show abstract

‘All illness is personal to that individual’: a qualitative study of patients’ perspectives on treatment adherence in bronchiectasis

Abstract: Background Adherence to treatment is low in bronchiectasis and is associated with poorer health outcomes. Factors affecting adherence decisions have not been explored in patients with bronchiectasis.

Cited by 23 publications

References 33 publications

Predictors of adherence to treatment in bronchiectasis

Predictors of adherence to treatment in bronchiectasis

Management of bronchiectasis in adults

Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration

Contact Info

Product

Resources

About